HEALTH.2013.2.4.1-2
HEALTH.2013.2.4.1-2
5 projects · €29,901,899 total EU contribution (project-level) · 39 participating organizations · 11 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€29,901,899
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (9)
- France (7)
- Italy (6)
- UK (5)
- CH (3)
- Spain (3)
- BE (1)
- FI (1)
- Netherlands (1)
- SE (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- UNIVERSITY OF NAVARRA2 projects · ES
- UNIVERSITE DE LAUSANNE2 projects · CH
- DEFINIENS AG1 projects · DE
- AYMING1 projects · FR
- BIOINVENT INTERNATIONAL AB1 projects · SE
- BIONTECH RNA PHARMACEUTICALS GMBH1 projects · DE
- CTX1 projects · FR
- CELLECTIS1 projects · FR
- CLB1 projects · FR
- CUREVAC AG1 projects · DE
- GERMAN CANCER RESEARCH CENTER1 projects · DE
- UT1 projects · DE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Immunostimulatory Agonist antibodies for Cancer Therapy IACT · 602262 | FP7 | €5,995,747 | €8,227,908 | Details |
Improving Prostate Cancer Outcome with Vectored Vaccines IMPROVE · 602705 | FP7 | €6,000,000 | €8,061,102 | Details |
Development of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers TUMADOR · 602200 | FP7 | €5,978,890 | €7,750,804 | Details |
Cancer Vaccine development for Hepatocellular Carcinoma HEPAVAC · 602893 | FP7 | €5,996,111 | €8,201,226 | Details |
Advanced T-cell Engineered for Cancer Therapy ATECT · 602239 | FP7 | €5,931,151 | €7,780,342 | Details |